Axa’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Axa’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22,672	Closed	-$96K	–	1348
2021 Q2	$96K	Sell	22,672 -39,100	-63%	-$165K	﹤0.01%	1243
2021 Q1	$308K	Hold	61,772	–	–	﹤0.01%	1136
2020 Q4	$781K	Hold	61,772	–	–	﹤0.01%	1012
2020 Q3	$607K	Buy	61,772 +15,317	+33%	+$151K	﹤0.01%	1005
2020 Q2	$462K	Sell	46,455 -27,628	-37%	-$265K	﹤0.01%	1073
2020 Q1	$655K	Hold	74,083	–	–	﹤0.01%	928
2019 Q4	$683K	Hold	74,083	–	–	﹤0.01%	945
2019 Q3	$436K	Sell	74,083 -31,400	-30%	-$333K	﹤0.01%	1120
2019 Q2	$1.27M	Buy	105,483 +77,583	+278%	+$834K	﹤0.01%	932
2019 Q1	$337K	Buy	+27,900	New	+$411K	﹤0.01%	1169
2018 Q4	–	Sell	-17,300	Closed	-$257K	–	1393
2018 Q3	$257K	Hold	17,300	–	–	﹤0.01%	1257
2018 Q2	$291K	Sell	17,300 -8,900	-34%	-$173K	﹤0.01%	1237
2018 Q1	$600K	Buy	+26,200	New	+$583K	﹤0.01%	1124

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Axa's CNCE Position: Q3 2021 in Review

Axa sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 22,672 shares — an estimated $96K sold.

Axa first reported a position in CNCE in Q1 2018 and held it in 13 quarters. The position peaked at $1.27M in Q2 2019. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

Axa reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Axa sold 22,672 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $96K.
Axa first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 13 quarters.
Axa's Concert Pharmaceuticals, Inc. position peaked at $1.27M in Q2 2019.
61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.